Skip to main content
Log in

Nitric oxide no more worthwhile than placebo in ARDS

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

REFERENCE

  1. Angus DC, Clermont G, Linde-Zwirble WT, Musthafa AA, Dremsizov TT, Lidicker J, Lave JR, NO-06 Investigators.Healthcare costs and long-term outcomes after acute respiratory distress syndrome: a phase III trial of inhaled nitric oxide. Critical Care Medicine 34: 2883-2890, No. 12, Dec 2006

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nitric oxide no more worthwhile than placebo in ARDS. Pharmacoecon. Outcomes News 521, 8 (2007). https://doi.org/10.2165/00151234-200705210-00025

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200705210-00025

Keywords

Navigation